Clinical trials: Pharmacogenomics, open to volunteers
Pharmacogenetics, Depression - Major Depressive Disorder
An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment…
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Trial name
- COMPASS-PGx (NCT07373470)
- Testing
- Comprehensive medication management with PGx testing results, Usual Care
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Pittsburgh
Pharmacogenomic Drug Interaction
Trial of Precision Medicine in Emergency Departments
The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision…
- Trial name
- TOPMEDs (NCT06448091)
- Testing
- Panel-based pharmacogenetic genotyping
- Where
- 3 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Florida
Stroke, Transient Ischemic Attack (TIA)
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic…
- Trial name
- CYP-FAST (NCT06943586)
- Testing
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Alabama at Birmingham
Adverse Drug Reaction (ADR), Polypharmacy Patients
IPGx PILOT Whole Genome Sequencing Extension Cohort
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make…
- Trial name
- NCT06766071
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Texas A&M University
Moderate to Severe Asthma
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment.
- Trial name
- EPIPHANY (NCT06385236)
- Testing
- Dupilumab, Benralizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Adverse Drug Reaction (ADR)
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to…
- Trial name
- NCT00414115
- Where
- Canada
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Metastatic Colorectal Cancer
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer).
- Trial name
- EVIDENT (NCT05725200)
- Testing
- Alectinib, Cetuximab, Crizotinib
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Ischemic Stroke, CYP2C19 Polymorphism
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
The goal of this observational study is to use a genetic test to help doctors prescribe the most effective medications after a patient has a stroke. One type of stroke is caused by a blood clot in brain vessels.
- Trial name
- ORCA-AIS (NCT06292117)
- Testing
- CYP2C19 Genotype
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- University of Virginia
Endometriosis Pelvic, Endometriosis Ovaries
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
PRECISION-E2 is a Phase IIa randomized, placebo-controlled study evaluating the pharmacodynamic profile, safety and tolerability of teverelix in premenopausal women with moderate-to-severe pain associated with endometriosis in…
- Conditions
- Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis)
- Trial name
- NCT07914062
- Testing
- Teverelix DP
- Volunteers
- 84 people
- Sponsor
- Antev Ltd.
Adverse Drug Reaction
The Texas Interprofessional Pharmacogenomics (IPGx)
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make…
- Trial name
- NCT06219720
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Texas A&M University
Pulmonary Embolism
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs). 2.
- Trial name
- NCT06362343
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Cancer, Cancer Diagnosis
Avera Cancer Sequencing and Analytics Protocol (ASAP)
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system.
- Conditions
- Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer
- Trial name
- ASAP (NCT05142033)
- Where
- 6 sites in United States
- Volunteers
- 25,000 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Acute Lymphoblastic Leukemia
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia.
- Trial name
- NCT03568266
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Southern California
Membranous Nephropathy
Omics of Rituximab-resistance
The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict response to RTX, ultimately…
- Trial name
- CONFUCIUS (NCT07416942)
- Testing
- Multi-omics Analysis, Sample collection
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Colorectal Neoplasms, Breast Neoplasms
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of…
- Conditions
- Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
- Trial name
- NCT07158164
- Testing
- Fluorouracil injection, Xeloda
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Rutgers, The State University of New Jersey
Preventive Cardiology, Respiration Disorders
"ADEN Platform: Pilot Clinical Validation for Chronic Disease Risk Stratification in Colombia"
This protocol describes a 90-day prospective pilot study designed to validate the capacity of the ADEN clinical intelligence platform to stratify early chronic disease risk across six priority public health profiles in Colombia.
- Conditions
- Preventive Cardiology, Respiration Disorders, Oncologic Disease, Autoimmune
- Trial name
- VALIDATES (NCT07727915)
- Testing
- Molecular Target
- Where
- Colombia
- Volunteers
- 120 people
- Sponsor
- Unidad de Investigación Genética Molecular
Pharmacogenomic Drug Interaction, Side Effect of Drug
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed…
- Conditions
- Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related
- Trial name
- PREPARE-Mayo (NCT06322238)
- Testing
- PGx panel test
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
Praegnant Breast Cancer: Early/Advanced/Metastatic
Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis.
- Trial name
- PRAEGNANT (NCT02338167)
- Testing
- Blood sampling
- Where
- 61 sites in Germany
- Volunteers
- 13,500 people
- Sponsor
- University Hospital Tuebingen
Depressive Disorder, Major Depressive Disorder, Suicidal Ideation
Evaluation of a Multi-Layered Digital Phenotyping, Digital Safety Plan, and Pharmacogenomic Intervention for Suicide Prevention in Adults With Depression
The goal of this clinical trial is to learn if a multi-layered digital and pharmacogenomic intervention works to prevent suicide re-attempts in adults with depression.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Suicidal Ideation, Suicide, Attempted, Suicide Prevention
- Trial name
- SMARTomicS (NCT07885722)
- Testing
- Digital Monitoring (Active/Passive EMA), Ecological Momentary Intervention (EMI) via Digital Safety Plan, Pharmacogenetic-Guided Care and Therapeutic Drug Monitoring
- Where
- Spain
- Volunteers
- 525 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz